东方海洋前三季度营收2.46亿元同比降0.78%，归母净利润-1.05亿元同比降51.43%，毛利率下降9.96个百分点

Core Insights - The company reported a revenue of 246 million yuan for the first three quarters of 2025, a year-on-year decrease of 0.78% [1] - The net profit attributable to shareholders was -105 million yuan, down 51.43% year-on-year, with a basic earnings per share of -0.05 yuan [1] - The gross margin for the first three quarters was 0.35%, a decline of 9.96 percentage points compared to the previous year [1] Financial Performance - The company’s net profit margin was -43.22%, a decrease of 14.87 percentage points year-on-year [1] - In Q3 2025, the gross margin was 2.54%, down 1.43 percentage points year-on-year but up 16.19 percentage points quarter-on-quarter [1] - The net profit margin for Q3 was -38.42%, a decline of 7.47 percentage points year-on-year, but an increase of 22.78 percentage points from the previous quarter [1] Expense Analysis - Total operating expenses for the period were 93.48 million yuan, a decrease of 3.68 million yuan year-on-year [2] - The expense ratio was 38.00%, down 1.19 percentage points from the previous year [2] - Sales expenses increased by 4.19%, while management and R&D expenses decreased by 7.57% and 13.31%, respectively [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 72,500, a decrease of 5,187 or 6.68% from the previous half [2] - The average market value per shareholder decreased from 71,400 yuan to 70,000 yuan, a decline of 1.93% [2] Company Overview - The company, Shandong Oriental Ocean Technology Co., Ltd., is located in Yantai, Shandong Province, and was established on December 19, 2001 [2] - The main business activities include seawater seed breeding, aquaculture, seafood processing, biotechnology, bonded warehousing logistics, and the R&D, production, and sales of in vitro diagnostic reagents [2] - The revenue composition includes processing of raw materials (47.77%), domestic trade (11.46%), and other segments [2] Industry Classification - The company belongs to the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sector [3] - It is associated with concepts such as gene sequencing, antigen testing, private hospitals, and pre-prepared dishes [3]